FLT3 and acute leukemia: The combination of sorafenib with clofarabine and cytarabine in pediatric relapsed/refractory acute leukemia patients showed good anti-leukemic activity and tolerability [159], with 83.3% (10/12) of patients displaying a decreased blast percentage, and 6 patients (3 FLT3-ITD+, 3 FLT3 wild-type) achieving CR.